Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers

University of Oxford399 enrolled

Overview

This study is to measure prevalence of established and candidate molecular markers of drug resistant malaria at Komé, Doba, Republic of Chad.

This is a cross-sectional, observational study using dried blood samples collected from P. falciparum-infected individuals at the time of malaria diagnosis to measure the prevalence of known and candidate molecular markers of resistance to artemisinin and non-artemisinin ACT partner drugs. A maximum of 200 participants will be enrolled at each participating site per year. Study duration is 2 years. Therefore total participant is up to 400. Prospective participants will have blood collected for dried blood spot (DBS) study sample after providing informed consent. Individuals with confirmed P. falciparum infection will have DBS samples included for molecular analyses for known and candidate molecular markers of antimalarial drug resistance.

Study Type

OBSERVATIONAL

Enrollment

399

Conditions

Plasmodium Falciparum

Eligibility

Sex: ALLMin age: 6 MonthsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: Participants must meet all of the inclusion criteria to participate in the study. * Patients (6 months - 75 years) with confirmed uncomplicated P. falciparum infection * Written informed consent obtained Exclusion Criteria: * Patients presenting signs of severe malaria will be excluded from the survey to prevent any delay in the management of the patient.

Locations (1)

Study clinic

Komé, Doba, Chad

Outcomes

Primary Outcomes

Percent prevalence of kelch13 mutants (marker of resistance to artemisinins)

Time frame: 2 years

Secondary Outcomes

Percent prevalence of specimens with pfmdr1 copy number >1 (marker of resistance to mefloquine)

Time frame: 2 years

Visualization and dissemination of molecular marker prevalence data to inform public health officials, researchers, policymakers and key stakeholders

Time frame: 2 yeas

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.